• Product launch timelines: Commercial launch of Zaynich in both the US and India is planned within 6 to 7 months, with a European rollout expected roughly a year after the US launch due to country-by-country pricing approvals.
• In-house commercial strategy: Wockhardt chose to commercialize Zaynich independently rather than out-license it, using an in-house model to capture an untapped global market for its pipeline of six novel antibiotics.
• Sales and margin targets: After aiming for break-even or modest profits in the initial 12 to 18 months, Zaynich's sales trajectory is expected to accelerate in FY29 toward peak annual sales of $1.5 billion to $2 billion, lifting company margins by at least 10% within 3 to 4 years.
• Pricing and liquidity: Zaynich will be offered in India at a 75% to 80% discount compared to US price points to broaden access, while existing liquidity is currently sufficient with no active plans to raise capital.